SL Science Holding Limited (SLBT)
NASDAQ: SLBT · Real-Time Price · USD
1.530
+0.020 (1.32%)
At close: Oct 13, 2026, 4:00 PM EDT
1.513
-0.017 (-1.14%)
After-hours: Oct 13, 2026, 7:30 PM EDT
Company Description
SL Science Holding Limited manufactures cosmetic skin care and scalp care products.
The company’s products include SL bio’s milk-derived exosome essence, SL bio’s tangerine-derived extract, and the MilkExo concentrate series.
It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes.
SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026.
The company is based in Taipei, Taiwan.
SL Science Holding Limited
| Country | Taiwan |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Ching-Dong Wang |
Contact Details
Address: No. 479, Chongyang Rd., 11th Floor, Nangang Dist. Taipei, 115010 Taiwan | |
| Phone | 886 2 2651 6826 |
| Website | sl-bio.com |
Stock Details
| Ticker Symbol | SLBT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2070534 |
| CUSIP Number | G8191L116 |
| ISIN Number | KYG8191L1169 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ching-Dong Wang | Founder, Chairman and Chief Executive Officer |
| Ray Leung | Chief Financial Officer and Director |
| Dr. Ethan Shen Ph.D. | Chief Technology Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 9, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 1, 2026 | SCHEDULE 13D/A | Filing |
| Sep 24, 2026 | 6-K | Report of foreign issuer |
| Sep 1, 2026 | 6-K | Report of foreign issuer |
| Aug 27, 2026 | 6-K | Report of foreign issuer |
| Aug 14, 2026 | 424B3 | Prospectus |
| Aug 12, 2026 | EFFECT | Notice of Effectiveness |
| Jul 31, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Jul 10, 2026 | 6-K | Report of foreign issuer |
| Jun 18, 2026 | SCHEDULE 13D | Filing |